Appointed key leadership to drive (Z)-endoxifen development and evolve pathway to commercialization SEATTLE, /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a ...

Company reports progress to file planned IND for (Z)-endoxifen in mBC with CRO selection and streamlined development programs for potential 2026-NDA enabling activities ...

The Nuclear Regulatory Commission may soon loosen radiation exposure safety standards at nuclear plants and operations.

Medical and health news service that features the most comprehensive coverage in the fields of neuroscience, cardiology, ...

A national quality improvement program led by the American College of Surgeons (ACS) found that transportation barriers and illness are among the top reasons cancer patients miss critical radiation ...